Birchview Capital, LP - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 237 filers reported holding NEKTAR THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.

Quarter-by-quarter ownership
Birchview Capital, LP ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2023$16,677
+3.5%
28,0000.0%0.01%
+16.7%
Q2 2023$16,106
+19304.8%
28,000
-76.3%
0.01%
-81.5%
Q1 2023$83
-68.9%
118,0000.0%0.06%
-65.6%
Q4 2022$267
-99.9%
118,000
-7.8%
0.19%
-34.6%
Q3 2022$410,000
-15.6%
128,0000.0%0.29%
-18.4%
Q2 2022$486,000
-29.6%
128,0000.0%0.35%
-28.8%
Q1 2022$690,000
-48.9%
128,000
+28.0%
0.50%
-42.9%
Q4 2021$1,351,000
+4.5%
100,000
+38.9%
0.87%
-1.0%
Q3 2021$1,293,000
+4.6%
72,0000.0%0.88%
+19.1%
Q2 2021$1,236,000
-32.8%
72,000
-21.7%
0.74%
-32.3%
Q1 2021$1,840,000
+444.4%
92,000
+868.4%
1.09%
+430.1%
Q2 2019$338,000
+6.0%
9,5000.0%0.21%
+3.0%
Q1 2019$319,000
+2.2%
9,5000.0%0.20%
-32.2%
Q4 2018$312,000
-46.1%
9,5000.0%0.30%
-21.1%
Q3 2018$579,000
+24.8%
9,5000.0%0.37%
+18.7%
Q2 2018$464,0009,5000.32%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q1 2021
NameSharesValueWeighting ↓
Camber Capital Management LP 3,500,000$60,060,0002.02%
ACT CAPITAL MANAGEMENT, LLC 161,500$2,772,0001.42%
Rhenman & Partners Asset Management AB 950,000$16,302,0001.11%
MAVERICK CAPITAL LTD 5,761,073$98,860,0000.93%
Birchview Capital, LP 72,000$1,236,0000.74%
Bellevue Group AG 4,101,404$70,380,0000.69%
CM Management, LLC 50,000$858,0000.62%
Duquesne Family Office 1,000,000$17,160,0000.42%
OSTERWEIS CAPITAL MANAGEMENT INC 373,368$6,407,0000.33%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 67,000$1,149,0000.30%
View complete list of NEKTAR THERAPEUTICS shareholders